NCT01489644 - Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers | Biotech Hunter

Enrollment

62

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

repaglinide

Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order

DRUG

metformin

Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order

DRUG

repaglinide and metformin combination tablet

Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order

Trial Locations (2)

33169

Novo Nordisk Investigational Site, Miami

98418

Novo Nordisk Investigational Site, Tacoma